Home » Strategic Plan Targets Development of Drugs for Pediatric Gaucher Disease
Strategic Plan Targets Development of Drugs for Pediatric Gaucher Disease
June 27, 2014
Clinical investigators looking to develop new therapies for children with Gaucher disease may use either multi-company, multi-arm trials or data extrapolation techniques, according to a joint strategic plan released by the U.S. Food and Drug Administration and European Medicines Agency.
To View This Article:
Subscribe To International Pharmaceutical Regulatory Monitor